scispace - formally typeset
Search or ask a question

Showing papers by "Oliver Hofmann published in 2017"


Journal ArticleDOI
23 Nov 2017-Nature
TL;DR: In this paper, the authors used genetic, immunohistochemical and transcriptional immunoprofiling, computational biophysics, and functional assays to identify T-cell antigens in long-term survivors of pancreatic cancer.
Abstract: Pancreatic ductal adenocarcinoma is a lethal cancer with fewer than 7% of patients surviving past 5 years. T-cell immunity has been linked to the exceptional outcome of the few long-term survivors, yet the relevant antigens remain unknown. Here we use genetic, immunohistochemical and transcriptional immunoprofiling, computational biophysics, and functional assays to identify T-cell antigens in long-term survivors of pancreatic cancer. Using whole-exome sequencing and in silico neoantigen prediction, we found that tumours with both the highest neoantigen number and the most abundant CD8+ T-cell infiltrates, but neither alone, stratified patients with the longest survival. Investigating the specific neoantigen qualities promoting T-cell activation in long-term survivors, we discovered that these individuals were enriched in neoantigen qualities defined by a fitness model, and neoantigens in the tumour antigen MUC16 (also known as CA125). A neoantigen quality fitness model conferring greater immunogenicity to neoantigens with differential presentation and homology to infectious disease-derived peptides identified long-term survivors in two independent datasets, whereas a neoantigen quantity model ascribing greater immunogenicity to increasing neoantigen number alone did not. We detected intratumoural and lasting circulating T-cell reactivity to both high-quality and MUC16 neoantigens in long-term survivors of pancreatic cancer, including clones with specificity to both high-quality neoantigens and predicted cross-reactive microbial epitopes, consistent with neoantigen molecular mimicry. Notably, we observed selective loss of high-quality and MUC16 neoantigenic clones on metastatic progression, suggesting neoantigen immunoediting. Our results identify neoantigens with unique qualities as T-cell targets in pancreatic ductal adenocarcinoma. More broadly, we identify neoantigen quality as a biomarker for immunogenic tumours that may guide the application of immunotherapies.

774 citations


Journal ArticleDOI
Jeremy L. Humphris1, Ann-Marie Patch2, Ann-Marie Patch3, Katia Nones3, Katia Nones2, Peter Bailey3, Peter Bailey4, Amber L. Johns1, Skye McKay1, David K. Chang, David Miller1, David Miller3, Marina Pajic5, Marina Pajic1, Karin S. Kassahn6, Karin S. Kassahn3, Michael C.J. Quinn2, Michael C.J. Quinn3, Timothy J. C. Bruxner3, Angelika N. Christ3, Ivon Harliwong3, Senel Idrisoglu3, Suzanne Manning3, Craig Nourse5, Craig Nourse3, Ehsan Nourbakhsh3, Andrew Stone1, Peter J. Wilson3, Matthew J. Anderson3, J. Lynn Fink3, Oliver Holmes2, Oliver Holmes3, Stephen H. Kazakoff2, Stephen H. Kazakoff3, Conrad Leonard2, Conrad Leonard3, Felicity Newell2, Felicity Newell3, Nick Waddell3, Scott Wood2, Scott Wood3, Ronald S Mead1, Qinying Xu3, Qinying Xu2, Jianmin Wu1, Mark Pinese1, Mark J. Cowley5, Mark J. Cowley1, Marc D. Jones1, Marc D. Jones4, Adnan Nagrial1, Venessa T. Chin1, Lorraine A. Chantrill7, Lorraine A. Chantrill1, Amanda Mawson1, Angela Chou8, Angela Chou1, Christopher J. Scarlett9, Christopher J. Scarlett1, Andreia V. Pinho1, Ilse Rooman1, Marc Giry-Laterriere1, Jaswinder S. Samra10, Jaswinder S. Samra11, James G. Kench12, James G. Kench10, James G. Kench1, Neil D. Merrett10, Christopher W. Toon1, Krishna Epari13, Nam Q. Nguyen14, Andrew Barbour15, Nikolajs Zeps16, Nigel B. Jamieson17, Nigel B. Jamieson4, Colin J. McKay17, C. Ross Carter17, Euan J. Dickson17, Janet Graham4, Janet Graham18, Fraser Duthie19, Karin A. Oien19, Jane Hair, Jennifer P. Morton4, Owen J. Sansom4, Robert Grützmann, Ralph H. Hruban20, Anirban Maitra20, Christine A. Iacobuzio-Donahue20, Richard D. Schulick20, Christopher L. Wolfgang20, Richard A. Morgan20, Rita T. Lawlor21, Borislav Rusev21, Vincenzo Corbo21, Roberto Salvia21, Ivana Cataldo21, Giampaolo Tortora, Margaret A. Tempero22, Oliver Hofmann4, James R. Eshleman20, Christian Pilarsky23, Aldo Scarpa21, Elizabeth A. Musgrove1, Elizabeth A. Musgrove5, Elizabeth A. Musgrove4, Anthony J. Gill10, Anthony J. Gill1, Anthony J. Gill11, John V. Pearson2, John V. Pearson3, Sean M. Grimmond3, Sean M. Grimmond24, Nicola Waddell2, Nicola Waddell3, Andrew V. Biankin 
TL;DR: Defining mutation load in individual pancreatic cancers and the optimal assay for patient selection may inform clinical trial design for immunotherapy in pancreatic cancer.

171 citations


Posted ContentDOI
09 Aug 2017-bioRxiv
TL;DR: It is demonstrated that most tumours are heterogeneous and harbour multiple signature exposures, and changes in signature exposure observed in response to chemotherapy suggest potential treatment strategies.
Abstract: Tumours with profound copy-number aberration elude molecular stratification due to their genomic complexity. By representing this complexity as a mixture of copy-number signatures, we provide molecular explanations for differing clinical outcomes. Here we present a method for copy-number signature identification, deriving eight signatures in 117 shallow whole-genome sequenced high-grade serous ovarian cancers (HGSOC), which validated on independent cohorts of 95 deep whole-genome sequenced, and 402 SNP array-profiled cases. Three copy-number signatures predicted longer overall survival, while the others predicted poorer outcome. We found evidence for the mutational processes giving rise to copy-number change for six of the eight signatures via correlations with other genomic features. Our results provide insights into the pathogenesis of HGSOC by uncovering multiple mutational processes that shape genomes following TP53 mutation. Importantly, our work shows that most HGSOC have a mixture of mutational processes suggesting that targeting a single mutator phenotype may be therapeutically suboptimal.

95 citations


Journal ArticleDOI
TL;DR: Genetic association and meta-analyses of the results in several large family-based and case-control late-onset familial Alzheimer's disease (LOAD) samples of SOX5 variants revealed several variants that show significant association with AD disease status, and analysis for rare and highly penetrate functional variants revealed four novel variants/mutations inSOX5.
Abstract: SOX5 encodes a transcription factor that is expressed in multiple tissues including heart, lung and brain. Mutations in SOX5 have been previously found in patients with amyotrophic lateral sclerosis (ALS) and developmental delay, intellectual disability and dysmorphic features. To characterize the neuronal role of SOX5, we silenced the Drosophila ortholog of SOX5, Sox102F, by RNAi in various neuronal subtypes in Drosophila. Silencing of Sox102F led to misorientated and disorganized michrochaetes, neurons with shorter dendritic arborization (DA) and reduced complexity, diminished larval peristaltic contractions, loss of neuromuscular junction bouton structures, impaired olfactory perception, and severe neurodegeneration in brain. Silencing of SOX5 in human SH-SY5Y neuroblastoma cells resulted in a significant repression of WNT signaling activity and altered expression of WNT-related genes. Genetic association and meta-analyses of the results in several large family-based and case-control late-onset familial Alzheimer's disease (LOAD) samples of SOX5 variants revealed several variants that show significant association with AD disease status. In addition, analysis for rare and highly penetrate functional variants revealed four novel variants/mutations in SOX5, which taken together with functional prediction analysis, suggests a strong role of SOX5 causing AD in the carrier families. Collectively, these findings indicate that SOX5 is a novel candidate gene for LOAD with an important role in neuronal function. The genetic findings warrant further studies to identify and characterize SOX5 variants that confer risk for AD, ALS and intellectual disability.

31 citations


Posted ContentDOI
Christina K. Yung1, Brian O'Connor1, Sergei Yakneen, Junjun Zhang1, Kyle Ellrott2, Kortine Kleinheinz3, Miyoshi N4, Raine Km5, Romina Royo6, Gordon Saksena7, Matthias Schlesner3, Solomon Shorser1, Miguel Vazquez, Joachim Weischenfeldt, Denis Yuen1, Adam Butler5, Brandi N. Davis-Dusenbery, Roland Eils3, Ferretti1, Robert L. Grossman8, Olivier Harismendy9, Yong Ho Kim10, Hidewaki Nakagawa, Steven Newhouse11, David Torrents6, Lincoln Stein1, Rodriguez Jb6, Keith A. Boroevich, Boyce R11, Angela N. Brooks12, Alex Buchanan2, Ivo Buchhalter13, Ivo Buchhalter3, Byrne Nj1, Andy Cafferkey11, Peter J. Campbell5, Zhao Chen9, Sung-Hoon Cho, Choi W14, Peter Clapham5, De La Vega Fm5, Jonas Demeulemeester15, Jonas Demeulemeester16, Michelle Dow9, L. J. Dursi1, Jürgen Eils3, Claudiu Farcas9, Francesco Favero17, Fayzullaev N1, Paul Flicek11, Nuno A. Fonseca11, Josep Lluís Gelpí6, Josep Lluís Gelpí18, Gad Getz19, Gad Getz7, Gibson B1, Michael Heinold13, Michael Heinold3, Julian M. Hess7, Oliver Hofmann20, Hong Jh, Thomas J. Hudson1, Daniel Huebschmann3, Daniel Huebschmann13, Barbara Hutter3, Carolyn M. Hutter21, Seiya Imoto4, Ivkovic S, Jeon S14, Wei Jiao1, Jongsun Jung, Rolf Kabbe3, André Kahles22, Jules Kerssemakers3, Kim H3, Jae H. Kim9, Jan O. Korbel11, Koscher M3, Koures A9, Kovacevic M, Christian Lawerenz3, Ignaty Leshchiner7, Dimitri Livitz7, Mihaiescu Gl1, Mijalkovic S, Lazic Am, Satoru Miyano4, Nahal Hk1, Nastic M, Nicholson J5, Ocana D11, Ohi K4, Lucila Ohno-Machado9, Larsson Omberg, Francis Ouellette B9, Nagarajan Paramasivam13, Nagarajan Paramasivam3, Perry1, Perry23, Todd Pihl, Manuel Prinz3, Montserrat Puiggròs6, Radovic P, Esther Rheinbay19, Esther Rheinbay7, Rosenberg Mw7, Rosenberg Mw19, Short C11, Heidi J. Sofia21, Jonathan Spring8, Adam J Struck2, Grace Tiao7, Tijanic N, Peter Van Loo15, Peter Van Loo16, Vicente D6, Jeremiah Wala19, Jeremiah Wala7, Zhining Wang, Johannes Werner3, April E. Williams9, Young-Choon Woo14, Adam Wright1, Qian Xiang1 
10 Jul 2017-bioRxiv
TL;DR: The International Cancer Genome Consortium’s Pan-Cancer Analysis of Whole Genomes (PCAWG) project aimed to categorize somatic and germline variations in both coding and non-coding regions in over 2,800 cancer patients to provide high-quality validated consensus variants for downstream analysis.
Abstract: The International Cancer Genome Consortium (ICGC)9s Pan-Cancer Analysis of Whole Genomes (PCAWG) project aimed to categorize somatic and germline variations in both coding and non-coding regions in over 2,800 cancer patients. To provide this dataset to the research working groups for downstream analysis, the PCAWG Technical Working Group marshalled ~800TB of sequencing data from distributed geographical locations; developed portable software for uniform alignment, variant calling, artifact filtering and variant merging; performed the analysis in a geographically and technologically disparate collection of compute environments; and disseminated high-quality validated consensus variants to the working groups. The PCAWG dataset has been mirrored to multiple repositories and can be located using the ICGC Data Portal. The PCAWG workflows are also available as Docker images through Dockstore enabling researchers to replicate our analysis on their own data.

26 citations


Journal ArticleDOI
TL;DR: bcbioRNASeq, a Bioconductor package that provides ready-to-render templates, objects and wrapper functions to post-process bcbio RNA sequencing output data, helps automate the generation of high-level RNA-seq reports, facilitating the quality control analyses, identification of differentially expressed genes and functional enrichment analyses.
Abstract: RNA-seq analysis involves multiple steps, from processing raw sequencing data to identifying, organizing, annotating, and reporting differentially expressed genes. bcbio is an open source, community-maintained framework providing automated and scalable RNA-seq methods for identifying gene abundance counts. We have developed bcbioRNASeq, a Bioconductor package that provides ready-to-render templates, objects and wrapper functions to post-process bcbio RNA sequencing output data. bcbioRNASeq helps automate the generation of high-level RNA-seq reports, facilitating the quality control analyses, identification of differentially expressed genes and functional enrichment analyses.

22 citations


Journal ArticleDOI
04 Apr 2017-PeerJ
TL;DR: This paper describes a tiered prioritisation approach to extract high impact gene fusion events from existing structural variant calls to best highlight likely cancer driving fusions, and considerably improves on the automated visualisation of the high impact structural variants.
Abstract: Sensitivity of short read DNA-sequencing for gene fusion detection is improving, but is hampered by the significant amount of noise composed of uninteresting or false positive hits in the data. In this paper we describe a tiered prioritisation approach to extract high impact gene fusion events from existing structural variant calls. Using cell line and patient DNA sequence data we improve the annotation and interpretation of structural variant calls to best highlight likely cancer driving fusions. We also considerably improve on the automated visualisation of the high impact structural variants to highlight the effects of the variants on the resulting transcripts. The resulting framework greatly improves on readily detecting clinically actionable structural variants.

15 citations